Breztri Aerosphere approved in the US for COPD
24 July 2020 07:00 BST Breztri Aerosphere approved in the US for the maintenance treatment of COPD Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies AstraZeneca's Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The approval by the US Food and Drug Administration (FDA) was based on positive results from the Phase III ETHOS trial in